Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969843676> ?p ?o ?g. }
- W2969843676 endingPage "3336" @default.
- W2969843676 startingPage "3327" @default.
- W2969843676 abstract "Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1% (KEYNOTE-010), in first-line setting PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents." @default.
- W2969843676 created "2019-08-29" @default.
- W2969843676 creator A5003014678 @default.
- W2969843676 creator A5004628000 @default.
- W2969843676 creator A5014381245 @default.
- W2969843676 creator A5015965477 @default.
- W2969843676 creator A5019522534 @default.
- W2969843676 creator A5020456545 @default.
- W2969843676 creator A5025474253 @default.
- W2969843676 creator A5031019737 @default.
- W2969843676 creator A5032094088 @default.
- W2969843676 creator A5035669120 @default.
- W2969843676 creator A5039693856 @default.
- W2969843676 creator A5047328504 @default.
- W2969843676 creator A5051933262 @default.
- W2969843676 creator A5062149201 @default.
- W2969843676 creator A5065449685 @default.
- W2969843676 creator A5067404851 @default.
- W2969843676 creator A5079782055 @default.
- W2969843676 creator A5087886547 @default.
- W2969843676 creator A5091532757 @default.
- W2969843676 date "2019-10-01" @default.
- W2969843676 modified "2023-09-26" @default.
- W2969843676 title "Pembrolizumab in lung cancer: current evidence and future perspectives" @default.
- W2969843676 cites W1538902372 @default.
- W2969843676 cites W1982488143 @default.
- W2969843676 cites W2039123767 @default.
- W2969843676 cites W2124427232 @default.
- W2969843676 cites W2145871366 @default.
- W2969843676 cites W2198093519 @default.
- W2969843676 cites W2257999935 @default.
- W2969843676 cites W2340636398 @default.
- W2969843676 cites W2484653942 @default.
- W2969843676 cites W2506327908 @default.
- W2969843676 cites W2527905628 @default.
- W2969843676 cites W2528861955 @default.
- W2969843676 cites W2529904548 @default.
- W2969843676 cites W2554270486 @default.
- W2969843676 cites W2616943335 @default.
- W2969843676 cites W2635951006 @default.
- W2969843676 cites W2726507447 @default.
- W2969843676 cites W2745840031 @default.
- W2969843676 cites W2756648224 @default.
- W2969843676 cites W2765696340 @default.
- W2969843676 cites W2795146418 @default.
- W2969843676 cites W2796582438 @default.
- W2969843676 cites W2890591279 @default.
- W2969843676 cites W2892095332 @default.
- W2969843676 cites W2892640821 @default.
- W2969843676 cites W2893839994 @default.
- W2969843676 cites W2893960509 @default.
- W2969843676 cites W2908928362 @default.
- W2969843676 cites W2910245285 @default.
- W2969843676 cites W2925446385 @default.
- W2969843676 cites W4210992155 @default.
- W2969843676 cites W4242460399 @default.
- W2969843676 doi "https://doi.org/10.2217/fon-2019-0073" @default.
- W2969843676 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31432705" @default.
- W2969843676 hasPublicationYear "2019" @default.
- W2969843676 type Work @default.
- W2969843676 sameAs 2969843676 @default.
- W2969843676 citedByCount "4" @default.
- W2969843676 countsByYear W29698436762020 @default.
- W2969843676 countsByYear W29698436762021 @default.
- W2969843676 countsByYear W29698436762022 @default.
- W2969843676 crossrefType "journal-article" @default.
- W2969843676 hasAuthorship W2969843676A5003014678 @default.
- W2969843676 hasAuthorship W2969843676A5004628000 @default.
- W2969843676 hasAuthorship W2969843676A5014381245 @default.
- W2969843676 hasAuthorship W2969843676A5015965477 @default.
- W2969843676 hasAuthorship W2969843676A5019522534 @default.
- W2969843676 hasAuthorship W2969843676A5020456545 @default.
- W2969843676 hasAuthorship W2969843676A5025474253 @default.
- W2969843676 hasAuthorship W2969843676A5031019737 @default.
- W2969843676 hasAuthorship W2969843676A5032094088 @default.
- W2969843676 hasAuthorship W2969843676A5035669120 @default.
- W2969843676 hasAuthorship W2969843676A5039693856 @default.
- W2969843676 hasAuthorship W2969843676A5047328504 @default.
- W2969843676 hasAuthorship W2969843676A5051933262 @default.
- W2969843676 hasAuthorship W2969843676A5062149201 @default.
- W2969843676 hasAuthorship W2969843676A5065449685 @default.
- W2969843676 hasAuthorship W2969843676A5067404851 @default.
- W2969843676 hasAuthorship W2969843676A5079782055 @default.
- W2969843676 hasAuthorship W2969843676A5087886547 @default.
- W2969843676 hasAuthorship W2969843676A5091532757 @default.
- W2969843676 hasConcept C121608353 @default.
- W2969843676 hasConcept C126322002 @default.
- W2969843676 hasConcept C143998085 @default.
- W2969843676 hasConcept C159654299 @default.
- W2969843676 hasConcept C203014093 @default.
- W2969843676 hasConcept C2776256026 @default.
- W2969843676 hasConcept C2777701055 @default.
- W2969843676 hasConcept C2777863537 @default.
- W2969843676 hasConcept C2780057760 @default.
- W2969843676 hasConcept C2781053074 @default.
- W2969843676 hasConcept C542903549 @default.
- W2969843676 hasConcept C71924100 @default.
- W2969843676 hasConceptScore W2969843676C121608353 @default.